# Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma

> **NCT01446562** · PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 34 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** Y90 Ibritumomab Tiuxetan RIT

## Key facts

- **NCT ID:** NCT01446562
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01446562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01446562, "Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01446562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*